UBS is backing CSL's recovery
UBS is backing CSL's recovery
About this video
Key points:
UBS has lifted its CSL price target to $225, arguing the business is becoming reliable again under interim CEO Gordon Naylor.
Lower plasma collection costs and a new fractionation system could support a sustained recovery in gross margins.
The incoming CEO and ongoing weakness in China's albumin market remain key risks to the recovery.
CSL is working to rebuild investor confidence after a difficult period. UBS head of Australian healthcare research David Lowe says the core plasma business is returning to the consistency that historically made it a reliable growth story, giving the company greater visibility over its earnings.
Demand for immunoglobulin has moderated to mid-single-digit growth, while selling prices have largely stabilised. However, lower plasma collection costs and a planned shift to a new fractionation system could provide a further lift to yields, supporting gross margin recovery over the coming years.
UBS has raised its price target to $225, seeing greater value in CSL's defensive growth profile. But the leadership transition remains important, while excess albumin inventory in China could keep pressure on prices for another year. Longer term, investors will be watching the rebuild of CSL's R&D pipeline and the benefits of its new fractionation infrastructure.